Orthocell Limited announced the appointment of Professor Fiona Wood AM to the Orthocell Board. This coincides with the retirement of Mr. Qi Xiao Zhou, who has served as a Member of Orthocell?s Board since 2012 and the transition of Dr. Stewart Washer from Executive Director to Non-Executive Director. All changes detailed above will be effective 01 November, 2023.

The appointment of Professor Wood follows the recent appointment of experienced Chairman Mr. John Van Der Wielen, and independent Non-Executive USA based Director Dr. Ravi Thadhani. Professor Fiona Wood is a well-known and highly respected West Australian, and Australian National Living Treasure, with more than 30 years? experience as a plastic and reconstructive surgeon.

Professor Wood was named Western Australian Citizen of the Year in 2003 and 2004, Australian of the Year in 2005 and Member of the Order of Australia (AM) in 2003 for her contribution to Medicine in the field of burns. Her revolutionary ?spray-on skin? treatment of serious burns, invented with colleague Marie Stoner, uses a patient?s own skin cells to help restore damaged skin and significantly reduce permanent scarring.

This treatment was instrumental in saving many lives in the aftermath of the Bali bombing in 2002. Professor Wood is currently a Consultant Plastic Surgeon at Fiona Stanley Hospital and Perth Children?s Hospital, and the Winthrop Professor of Surgery at the University of Western Australia. Professor Wood is co-founder of the Wood Foundation, which continues her research into the treatment of burns and is a Board member of the Royal Flying Doctor Service, amongst others.

Following Professor Woods?s appointment and the resignation of Mr. Zhou, the Orthocell Board has six Directors comprising four Non-Executive Directors and two Executive Directors. With the experienced Board and management team, market leading products and strong balance sheet, the Company is well positioned to grow product sales alongside distribution partners, BioHorizons and Device Technologies, and to execute its US market access program and commercialisation strategies for its breakthrough nerve repair medical device.